

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
18 September 2003 (18.09.2003)

PCT

(10) International Publication Number
WO 03/076635 A1(51) International Patent Classification⁷: C12P 13/04,
13/08, C12N 1/21, 15/11, 15/60(74) Common Representative: DEGUSSA AG; Intellectual
Property Management, Patente und Marken, Standort
Hanau, Postfach 13 45, 63403 Hanau (DE).

(21) International Application Number: PCT/EP03/01992

(81) Designated States (*national*): BR, CN, KR, MX, PL, US.

(22) International Filing Date: 27 February 2003 (27.02.2003)

(84) Designated States (*regional*): European patent (AT, BE,
BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU,
IE, IT, LU, MC, NL, PT, SE, SI, SK, TR).

(25) Filing Language: English

(26) Publication Language: English

Declarations under Rule 4.17:

(30) Priority Data:
102 10 962.1 13 March 2002 (13.03.2002) DE
60/365,837 21 March 2002 (21.03.2002) US

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations BR, CN, KR, MX, PL, European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR)
- of inventorship (Rule 4.17(iv)) for US only

(71) Applicant (*for all designated States except US*): DE-
GUSSA AG [DE/DE]; Bennigsenplatz 1, 40474 Düssel-
dorf (DE).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): RIEPING,
Mechthild [DE/DE]; Mönkebergstrasse 1, 33619 Biele-
feld (DE). HERMANN, Thomas [DE/DE]; Zirkonstrasse
8, 33739 Bielefeld (DE). FARWICK, Mike [DE/DE];
Gustav-Adolf-Strasse 11, 33615 Bielefeld (DE).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 03/076635 A1

(54) Title: PROCESS FOR THE PREPARATION OF L-AMINO ACIDS USING STRAINS OF THE FAMILY ENTEROBACTERIACEAE

(57) The invention relates to a process for the preparation of L-amino acids. The process is carried out: a) fermentation of microorganisms of the family Enterobacteriaceae which produce the desired L-amino acid and in which at least one or more genes selected from the group comprising *lpd*, *aceE* and *aceF*, or nucleotide sequences coding therefor, is (are) enhanced and, in particular, overexpressed, b) enrichment of the desired L-amino acid in the medium or in the cells of the bacteria and c) isolation of the desired L-amino acid.

**Process for the Preparation of L-Amino Acids using
Strains of the Family Enterobacteriaceae**

Field of the Invention

The present invention relates to a process for the
5 preparation of L-amino acids, especially L-threonine, using
strains of the family Enterobacteriaceae in which at least
one or more genes selected from the group comprising *lpd*,
aceE and *aceF* is (are) enhanced.

State of the Art

10 L-Amino acids, especially L-threonine, are used in human
medicine and in the pharmaceutical industry, in the food
industry and very particularly in animal nutrition.

It is known to prepare L-amino acids by the fermentation of
strains of Enterobacteriaceae, especially *Escherichia coli*
15 (*E. coli*) and *Serratia marcescens*. Because of their great
importance, attempts are constantly being made to improve
the preparative processes. Improvements to the processes
may relate to measures involving the fermentation
technology, e.g. stirring and oxygen supply, or the
20 composition of the nutrient media, e.g. the sugar concen-
tration during fermentation, or the work-up to the product
form, e.g. by ion exchange chromatography, or the intrinsic
productivity characteristics of the microorganism itself.

The productivity characteristics of these microorganisms
25 are improved by using methods of mutagenesis, selection and
mutant choice to give strains which are resistant to
antimetabolites, e.g. the threonine analog α -amino- β -
hydroxyvaleric acid (AHV), or auxotrophic for metabolites
of regulatory significance, and produce L-amino acids, e.g.
30 L-threonine.

Methods of recombinant DNA technology have also been used
for some years to improve L-amino acid-producing strains of

the family Enterobacteriaceae by amplifying individual amino acid biosynthesis genes and studying the effect on production.

Object of the Invention

- 5 The object which the inventors set themselves was to provide novel procedures for improving the preparation of L-amino acids, especially L-threonine.

Summary of the Invention

- 10 The invention provides a process for the preparation of L-amino acids, especially L-threonine, using microorganisms of the family Enterobacteriaceae which, in particular, already produce L-amino acids and in which at least one or more of the nucleotide sequences coding for the genes *lpd*, *aceE* and *aceF* is (are) enhanced.

15 Detailed Description of the Invention

- The term "L-amino acids" or "amino acids" mentioned hereafter is to be understood as meaning one or more amino acids, including their salts, selected from the group comprising L-asparagine, L-threonine, L-serine, L-
20 glutamate, L-glycine, L-alanine, L-cysteine, L-valine, L-methionine, L-isoleucine, L-leucine, L-tyrosine, L-phenylalanine, L-histidine, L-lysine, L-tryptophan and L-arginine. L-Threonine is particularly preferred.

- In this context the term "enhancement" describes the
25 increase, in a microorganism, of the intracellular activity of one or more enzymes or proteins coded for by the appropriate DNA, for example by increasing the copy number of the gene or genes, using a strong promoter or a gene or allele coding for an appropriate enzyme or protein with a
30 high activity, and optionally combining these measures.

Through the measures of enhancement, especially over-expression, the activity or concentration of the appropriate protein is generally increased at least by 10%, 25%, 50%, 75%, 100%, 150%, 200%, 300%, 400% or 500%, and at
5 most by up to 1000% or 2000%, based on that of the wild-type protein or the activity or concentration of the protein in the starting microorganism.

The process is characterized in that the following steps are carried out:

- 10 a) fermentation of microorganisms of the family Enterobacteriaceae which produce the desired L-amino acid and in which one or more genes selected from the group comprising *lpd*, *aceE* and *aceF*, or nucleotide
15 sequences coding therefor, is (are) enhanced and, in particular, overexpressed,
- b) enrichment of the desired L-amino acid in the medium or in the cells of the microorganisms, and
- c) isolation of the desired L-amino acid, where
20 constituents of the fermentation broth, and/or all or part (≥ 0 to 100%) of the biomass, optionally remain in the product.

The microorganisms provided by the present invention can produce L-amino acids from glucose, sucrose, lactose, fructose, maltose, molasses, optionally starch or
25 optionally cellulose, or from glycerol and ethanol. Said microorganisms are representatives of the family Enterobacteriaceae selected from the genera *Escherichia*, *Erwinia*, *Providencia* and *Serratia*. The genera *Escherichia* and *Serratia* are preferred. The species *Escherichia coli*
30 and *Serratia marcescens* may be mentioned in particular among the genera *Escherichia* and *Serratia* respectively.

Examples of suitable strains, particularly L-threonine-producing strains, of the genus *Escherichia*, and especially of the species *Escherichia coli*, are:

- Escherichia coli TF427
- 5 Escherichia coli H4578
- Escherichia coli KY10935
- Escherichia coli VNIIGenetika MG442
- Escherichia coli VNIIGenetika M1
- Escherichia coli VNIIGenetika 472T23
- 10 Escherichia coli BKIIM B-3996
- Escherichia coli kat 13
- Escherichia coli KCCM-10132

Examples of suitable L-threonine-producing strains of the genus *Serratia*, and especially of the species *Serratia*
15 *marcescens*, are:

- Serratia marcescens* HNr21
- Serratia marcescens* TLr156
- Serratia marcescens* T2000.

- L-Threonine-producing strains of the family
- 20 Enterobacteriaceae preferably possess, inter alia, one or more genetic or phenotypic characteristics selected from the group comprising resistance to α -amino- β -hydroxyvaleric acid, resistance to thialysine, resistance to ethionine, resistance to α -methylserine, resistance to diaminosuccinic
 - 25 acid, resistance to α -aminobutyric acid, resistance to borrelidine, resistance to rifampicin, resistance to valine analogs such as valine hydroxamate, resistance to purine analogs such as 6-dimethylaminopurine, need for L-methionine, optionally partial and compensable need for L-
 - 30 isoleucine, need for meso-diaminopimelic acid, auxotrophy in respect of threonine-containing dipeptides, resistance to L-threonine, resistance to L-homoserine, resistance to L-lysine, resistance to L-methionine, resistance to L-glutamic acid, resistance to L-aspartate, resistance to L-

leucine, resistance to L-phenylalanine, resistance to L-serine, resistance to L-cysteine, resistance to L-valine, sensitivity to fluoropyruvate, defective threonine dehydrogenase, optionally capability for sucrose
5 utilization, enhancement of the threonine operon, enhancement of homoserine dehydrogenase I-aspartate kinase I, preferably of the feedback-resistant form, enhancement of homoserine kinase, enhancement of threonine synthase, enhancement of aspartate kinase, optionally of the
10 feedback-resistant form, enhancement of aspartate semialdehyde dehydrogenase, enhancement of phosphoenolpyruvate carboxylase, optionally of the feedback-resistant form, enhancement of phosphoenolpyruvate synthase, enhancement of transhydrogenase, enhancement of
15 the RhtB gene product, enhancement of the RhtC gene product, enhancement of the YfiK gene product, enhancement of a pyruvate carboxylase and attenuation of acetic acid formation.

It has been found that the production of L-amino acids,
20 especially L-threonine, by microorganisms of the family Enterobacteriaceae is improved after enhancement and, in particular, over-expression of at least one or more genes selected from the group comprising lpd, aceE and aceF.

The nucleotide sequences of the genes of *Escherichia coli*
25 belong to the state of the art (cf. literature references below) and can also be taken from the genome sequence of *Escherichia coli* published by Blattner et al. (Science 277, 1453-1462 (1997)).

The lpd, aceE and aceF genes are described inter alia by
30 the following data:

lpd gene

Name: dihydrolipoamide dehydrogenase (NADH-dependent), component of 2-oxodehydrogenase and E3 component of the pyruvate dehydrogenase complex, L-protein of the glycine scission complex

EC no.: 1.8.1.4

Reference: Stephens et al.; European Journal of Biochemistry 135(3), 519-527 (1983)
Steiert et al.; Journal of Bacteriology 172, 6142-6144 (1990)

Accession no.: AE000121

Alternative names: dldH, lpdA

aceE gene

Name: pyruvate dehydrogenase, E1 component of the pyruvate dehydrogenase complex, decarboxylase component

EC no.: 1.2.4.1

Reference: Stephens et al.; European Journal of Biochemistry 133(1), 155-162 (1983)
Guest et al.; Annals of the New York Academy of Sciences 573, 76-99 (1989)

Accession no.: AE000120

aceF gene

Name: dihydrolipoamide acetyltransferase, E2 component of the pyruvate dehydrogenase complex

EC no.: 2.3.1.12

Reference: Stephens et al.; European Journal of Biochemistry 133(3), 481-489 (1983)
Guest et al.; Annals of the New York Academy of Sciences 573, 76-99 (1989)

Accession no.: AE000120

The nucleic acid sequences can be taken from the data banks of the National Center for Biotechnology Information (NCBI)

of the National Library of Medicine (Bethesda, MD, USA),
the nucleotide sequence data bank of the European Molecular
Biologies Laboratories (EMBL, Heidelberg, Germany, or
Cambridge, UK) or the DNA Databank of Japan (DDBJ, Mishima,
5 Japan).

The genes described in the literature references cited can
be used according to the invention. It is also possible to
use alleles of the genes which result from the degeneracy
of the genetic code or from neutral sense mutations. The
10 use of endogenous genes is preferred.

The term "endogenous genes" or "endogenous nucleotide
sequences" is to be understood as meaning the genes or
alleles, or nucleotide sequences, present in the population
of a species.

15 Enhancement can be achieved for example by increasing the
expression of the genes or enhancing the catalytic
properties of the proteins. Both measures may optionally
be combined.

Over-expression can be achieved by increasing the copy
20 number of the appropriate genes or mutating the promoter
and regulatory region or the ribosome binding site located
upstream from the structural gene. Expression cassettes
incorporated upstream from the structural gene work in the
same way. Inducible promoters additionally make it
25 possible to increase expression in the course of L-
threonine production by fermentation. Measures for
prolonging the life of the mRNA also improve expression.
Furthermore, the enzyme activity is also enhanced by
preventing the degradation of the enzyme protein. The
30 genes or gene constructs can either be located in plasmids
of variable copy number or be integrated and amplified in
the chromosome. Alternatively, it is also possible to
achieve over-expression of the genes in question by

changing the composition of the media and the culture technique.

Those skilled in the art will find relevant instructions inter alia in Chang and Cohen (Journal of Bacteriology 134, 1141-1156 (1978)), Hartley and Gregori (Gene 13, 347-353 (1981)), Amann and Brosius (Gene 40, 183-190 (1985)), de Broer et al. (Proceedings of the National Academy of Sciences of the United States of America 80, 21-25 (1983)), LaVallie et al. (BIO/TECHNOLOGY 11, 187-193 (1993)),
10 PCT/US97/13359, Llosa et al. (Plasmid 26, 222-224 (1991)), Quandt and Klipp (Gene 80, 161-169 (1989)), Hamilton et al. (Journal of Bacteriology 171, 4617-4622 (1989)), Jensen and Hammer (Biotechnology and Bioengineering 58, 191-195 (1998)) and well-known textbooks on genetics and molecular
15 biology.

Plasmid vectors replicable in Enterobacteriaceae, e.g. cloning vectors derived from pACYC184 (Bartolomé et al.; Gene 102, 75-78 (1991)), pTrc99A (Amann et al.; Gene 69, 301-315 (1988)) or pSC101 derivatives (Vocke and Bastia;
20 Proceedings of the National Academy of Sciences USA 80(21), 6557-6561 (1983)), can be used. In one process according to the invention, it is possible to use a strain transformed with a plasmid vector, said plasmid vector carrying at least one or more genes selected from the group
25 comprising *lpd*, *aceE* and *aceF*, or nucleotide sequences coding therefor.

Also, mutations which affect the expression of the appropriate genes can be transferred to different strains by sequence exchange (Hamilton et al.; Journal of
30 Bacteriology 171, 4617-4622 (1989)), conjugation or transduction.

Furthermore, for the production of L-amino acids, especially L-threonine, with strains of the family Enterobacteriaceae, it can be advantageous not only to

enhance one or more genes selected from the group comprising *lpd*, *aceE* and *aceF*, but also to enhance one or more enzymes of the known threonine biosynthetic pathway, or enzymes of the anaplerotic metabolism, or enzymes for
5 the production of reduced nicotinamide adenine dinucleotide phosphate, or glycolytic enzymes, or PTS enzymes or enzymes of sulfur metabolism. The use of endogenous genes is generally preferred.

Thus, for example, one or more genes selected from the
10 group comprising:

- the *thrABC* operon coding for aspartate kinase, homoserine dehydrogenase, homoserine kinase and threonine synthase (US-A-4,278,765),
- the *pyc* gene coding for pyruvate carboxylase (DE-A-19 831
15 609),
- the *pps* gene coding for phosphoenolpyruvate synthase (Molecular and General Genetics 231(2), 332-336 (1992)),
- the *ppc* gene coding for phosphoenolpyruvate carboxylase (Gene 31, 279-283 (1984)),
- 20 • the *pntA* and *pntB* genes coding for transhydrogenase (European Journal of Biochemistry 158, 647-653 (1986)),
- the *rhtB* gene for homoserine resistance (EP-A-0 994 190),
- the *mgo* gene coding for malate:quinone oxidoreductase (DE 100 348 33.5),
- 25 • the *rhtC* gene for threonine resistance (EP-A-1 013 765),
- the *thrE* gene of *Corynebacterium glutamicum* coding for threonine export protein (DE 100 264 94.8),

- the *gdhA* gene coding for glutamate dehydrogenase (Nucleic Acids Research 11, 5257-5266 (1983); Gene 23, 199-209 (1983)),
- the *hns* gene coding for DNA binding protein HLP-II
5 (Molecular and General Genetics 212, 199-202 (1988)),
- the *pgm* gene coding for phosphoglucomutase (Journal of Bacteriology 176, 5847-5851 (1994)),
- the *fba* gene coding for fructose biphosphate aldolase (Biochemical Journal 257, 529-534 (1989)),
- 10 • the *ptsH* gene of the *ptsHIcrr* operon coding for phosphohistidine protein hexose phosphotransferase of the phosphotransferase system PTS (Journal of Biological Chemistry 262, 16241-16253 (1987)),
- the *ptsI* gene of the *ptsHIcrr* operon coding for enzyme I
15 of the phosphotransferase system PTS (Journal of Biological Chemistry 262, 16241-16253 (1987)),
- the *crr* gene of the *ptsHIcrr* operon coding for the glucose-specific IIA component of the phosphotransferase system PTS (Journal of Biological Chemistry 262, 16241-
20 16253 (1987)),
- the *ptsG* gene coding for the glucose-specific IIBC component (Journal of Biological Chemistry 261, 16398-16403 (1986)),
- the *lrp* gene coding for the regulator of the leucine
25 regulon (Journal of Biological Chemistry 266, 10768-10774 (1991)),
- the *csrA* gene coding for the global regulator Csr (Journal of Bacteriology 175, 4744-4755 (1993)),
- the *fadR* gene coding for the regulator of the *fad* regulon
30 (Nucleic Acids Research 16, 7995-8009 (1988)),

- the *iclR* gene coding for the regulator of the central intermediary metabolism (Journal of Bacteriology 172, 2642-2649 (1990)),
- the *mopB* gene coding for the 10 kd chaperone (Journal of Biological Chemistry 261, 12414-12419 (1986)), which is also known as *groES*,
- the *ahpC* gene of the *ahpCF* operon coding for the small subunit of alkyl hydroperoxide reductase (Proceedings of the National Academy of Sciences USA 92, 7617-7621 (1995)),
- the *ahpF* gene of the *ahpCF* operon coding for the large subunit of alkyl hydroperoxide reductase (Proceedings of the National Academy of Sciences USA 92, 7617-7621 (1995)),
- the *cysK* gene coding for cysteine synthase A (Journal of Bacteriology 170, 3150-3157 (1988)),
- the *cysB* gene coding for the regulator of the *cys* regulon (Journal of Biological Chemistry 262, 5999-6005 (1987)),
- the *cysJ* gene of the *cysJIH* operon coding for the flavoprotein of NADPH sulfite reductase (Journal of Biological Chemistry 264, 15796-15808 (1989), Journal of Biological Chemistry 264, 15726-15737 (1989)),
- the *cysI* gene of the *cysJIH* operon coding for the hemoprotein of NADPH sulfite reductase (Journal of Biological Chemistry 264, 15796-15808 (1989), Journal of Biological Chemistry 264, 15726-15737 (1989)),
- the *cysH* gene of the *cysJIH* operon coding for adenylyl sulfate reductase (Journal of Biological Chemistry 264, 15796-15808 (1989), Journal of Biological Chemistry 264, 15726-15737 (1989)),

- the phoB gene of the phoBR operon coding for the PhoB positive regulator of the pho regulon (Journal of Molecular Biology 190 (1), 37-44 (1986)),
- the phoR gene of the phoBR operon coding for the sensor protein of the pho regulon (Journal of Molecular Biology 192 (3), 549-556 (1986)),
- the phoE gene coding for protein E of the outer cell membrane (Journal of Molecular Biology 163 (4), 513-532 (1983)),
- 10 • the pykF gene coding for fructose-stimulated pyruvate kinase I (Journal of Bacteriology 177 (19), 5719-5722 (1995)),
- the pfkB gene coding for 6-phosphofructokinase II (Gene 28 (3), 337-342 (1984)),
- 15 • the malE gene coding for the periplasmatic binding protein of maltose transport (Journal of Biological Chemistry 259 (16), 10606-10613 (1984)),
- the rseA gene of the rseABC operon coding for a membrane protein with anti-sigmaE activity (Molecular Microbiology 24 (2), 355-371 (1997)),
- 20 • the rseC gene of the rseABC operon coding for a global regulator of the sigmaE factor (Molecular Microbiology 24 (2), 355-371 (1997)),
- the sodA gene coding for superoxide dismutase (Journal of Bacteriology 155 (3), 1078-1087 (1983)),
- 25 • the sucA gene of the sucABCD operon coding for the decarboxylase subunit of 2-ketoglutarate dehydrogenase (European Journal of Biochemistry 141 (2), 351-359 (1984)),

- the *sucB* gene of the *sucABCD* operon coding for the dihydrolipoyl transsuccinase E2 subunit of 2-ketoglutarate dehydrogenase (European Journal of Biochemistry 141 (2), 361-374 (1984)),
- 5 • the *sucC* gene of the *sucABCD* operon coding for the β subunit of succinyl-CoA synthetase (Biochemistry 24 (22), 6245-6252 (1985)), and
- the *sucD* gene of the *sucABCD* operon coding for the α subunit of succinyl-CoA synthetase (Biochemistry 24 (22),
10 6245-6252 (1985))

can be simultaneously enhanced and, in particular, overexpressed.

Furthermore, for the production of L-amino acids, especially L-threonine, it can be advantageous not only to
15 enhance one or more genes selected from the group comprising *lpd*, *aceE* and *aceF*, but also to attenuate and, in particular, switch off one or more genes selected from the group comprising:

- the *tdh* gene coding for threonine dehydrogenase (Journal
20 of Bacteriology 169, 4716-4721 (1987)),
- the *mdh* gene coding for malate dehydrogenase (E.C. 1.1.1.37) (Archives in Microbiology 149, 36-42 (1987)),
- the gene product of the open reading frame (orf) *yjfa* (Accession Number AAC77180 of the National Center for
25 Biotechnology Information (NCBI, Bethesda, MD, USA)),
- the gene product of the open reading frame (orf) *ytfP* (Accession Number AAC77179 of the National Center for Biotechnology Information (NCBI, Bethesda, MD, USA)),
- the *pckA* gene coding for the enzyme phosphoenolpyruvate
30 carboxykinase (Journal of Bacteriology 172, 7151-7156 (1990)),

- the poxB gene coding for pyruvate oxidase (Nucleic Acids Research 14 (13), 5449-5460 (1986)),
- the aceA gene coding for the enzyme isocitrate lyase (Journal of Bacteriology 170, 4528-4536 (1988)),
- 5 • the dgsA gene coding for the DgsA regulator of the phosphotransferase system (Bioscience, Biotechnology and Biochemistry 59, 256-261 (1995)), which is also known as the mlc gene,
- the fruR gene coding for the fructose repressor
- 10 (Molecular and General Genetics 226, 332-336 (1991)), which is also known as the cra gene,
- the rpoS gene coding for the sigma³⁸ factor (WO 01/05939), which is also known as the katF gene,
- the aspA gene coding for aspartate ammonium lyase
- 15 (aspartase) (Nucleic Acids Research 13 (6), 2063-2074 (1985)), and
- the aceB gene coding for malate synthase A (Nucleic Acids Research 16 (19), 9342 (1988)),

or reduce the expression.

- 20 In this context the term "attenuation" describes the decrease or switching-off of the intracellular activity, in a microorganism, of one or more enzymes (proteins) coded for by the appropriate DNA, for example by using a weak promoter or using a gene or allele which codes for an
- 25 appropriate enzyme with a low activity or inactivates the appropriate enzyme (protein) or gene, and optionally combining these measures.

The attenuation measures generally reduce the activity or concentration of the appropriate protein to 0 to 75%, 0 to

30 50%, 0 to 25%, 0 to 10% or 0 to 5% of the activity or concentration of the wild-type protein or of the activity

or concentration of the protein in the starting microorganism.

Furthermore, for the production of L-amino acids, especially L-threonine, it can be advantageous not only to
5 enhance one or more genes selected from the group comprising *lpd*, *aceE* and *aceF*, but also to switch off unwanted secondary reactions (Nakayama: "Breeding of Amino Acid Producing Microorganisms", in: Overproduction of Microbial Products, Krumphanzl, Sikyta, Vanek (eds.),
10 Academic Press, London, UK, 1982).

The microorganisms prepared according to the invention can be cultivated by the batch process, the fed batch process or the repeated fed batch process. A summary of known cultivation methods is provided in the textbook by Chmiel
15 (Bioprozesstechnik 1. Einführung in die Bioverfahrenstechnik (Bioprocess Technology 1. Introduction to Bioengineering) (Gustav Fischer Verlag, Stuttgart, 1991)) or in the textbook by Storhas (Bioreaktoren und periphere Einrichtungen (Bioreactors and Peripheral
20 Equipment) (Vieweg Verlag, Brunswick/Wiesbaden, 1994)).

The culture medium to be used must appropriately meet the demands of the particular strains. Descriptions of culture media for various microorganisms can be found in "Manual of Methods for General Bacteriology" of the American Society
25 for Bacteriology (Washington DC, USA, 1981).

Carbon sources which can be used are sugars and carbohydrates, e.g. glucose, sucrose, lactose, fructose, maltose, molasses, starch and optionally cellulose, oils and fats, e.g. soya oil, sunflower oil, groundnut oil and
30 coconut fat, fatty acids, e.g. palmitic acid, stearic acid and linoleic acid, alcohols, e.g. glycerol and ethanol, and organic acids, e.g. acetic acid. These substances can be used individually or as a mixture.

Nitrogen sources which can be used are organic nitrogen-containing compounds such as peptones, yeast extract, meat extract, malt extract, corn steep liquor, soya flour and urea, or inorganic compounds such as ammonium sulfate,
5 ammonium chloride, ammonium phosphate, ammonium carbonate and ammonium nitrate. The nitrogen sources can be used individually or as a mixture.

Phosphorus sources which can be used are phosphoric acid, potassium dihydrogenphosphate or dipotassium
10 hydrogenphosphate or the corresponding sodium salts. The culture medium must also contain metal salts, e.g. magnesium sulfate or iron sulfate, which are necessary for growth. Finally, essential growth-promoting substances such as amino acids and vitamins can be used in addition to
15 the substances mentioned above. Suitable precursors can also be added to the culture medium. Said feed materials can be added to the culture all at once or fed in appropriately during cultivation.

The fermentation is generally carried out at a pH of 5.5 to
20 9.0, especially of 6.0 to 8.0. The pH of the culture is controlled by the appropriate use of basic compounds such as sodium hydroxide, potassium hydroxide, ammonia or aqueous ammonia, or acid compounds such as phosphoric acid or sulfuric acid. Foaming can be controlled using
25 antifoams such as fatty acid polyglycol esters. The stability of plasmids can be maintained by adding suitable selectively acting substances, e.g. antibiotics, to the medium. Aerobic conditions are maintained by introducing oxygen or oxygen-containing gaseous mixtures, e.g. air,
30 into the culture. The temperature of the culture is normally 25°C to 45°C and preferably 30°C to 40°C. The culture is continued until the formation of L-amino acids or L-threonine has reached a maximum. This objective is normally achieved within 10 hours to 160 hours.

L-Amino acids can be analyzed by means of anion exchange chromatography followed by ninhydrin derivation, as described by Spackman et al. (Analytical Chemistry 30, 1190-1206 (1958)), or by reversed phase HPLC, as described
5 by Lindroth et al. (Analytical Chemistry 51, 1167-1174 (1979)).

The process according to the invention is used for the preparation of L-amino acids, e.g. L-threonine, L-isoleucine, L-valine, L-methionine, L-homoserine and L-
10 lysine, especially L-threonine, by fermentation.

The present invention is illustrated in greater detail below with the aid of Examples.

The minimum medium (M9) and complete medium (LB) used for Escherichia coli are described by J.H. Miller (A Short
15 Course in Bacterial Genetics (1992), Cold Spring Harbor Laboratory Press). The isolation of plasmid DNA from Escherichia coli and all the techniques for restriction, ligation, Klenow treatment and alkaline phosphatase treatment are carried out according to Sambrook et al.
20 (Molecular Cloning - A Laboratory Manual (1989), Cold Spring Harbor Laboratory Press). The transformation of Escherichia coli is carried out according to Chung et al. (Proceedings of the National Academy of Sciences of the United States of America 86, 2172-2175 (1989)) or according
25 to Chuang et al. (Nucleic Acids Research 23, 1641 (1995)).

The incubation temperature in the preparation of strains and transformants is 37°C.

Example 1

Preparation of L-threonine using the lpd gene

30 1a) Construction of expression plasmid pTrc99Alpd

The *lpd* gene from *E. coli* K12 is amplified using the polymerase chain reaction (PCR) and synthetic oligonucleotides. The nucleotide sequence of the *lpd* gene in *E. coli* K12 MG1655 (Accession Number AE000121, Blattner et al. (Science 277 (5331), 1453-1474 (1997))) is used as the starting material to synthesize PCR primers (MWG Biotech, Ebersberg, Germany). The 5' ends of the primers are extended with recognition sequences for restriction enzymes and with two to four additional bases. This part of the primer is identified by a hyphen (-) in the representation below. The recognition sequences for *Nco*I and *Sal*I, which are underlined in the nucleotide sequences shown below, are chosen for the 5' and 3' primers respectively:

15 *lpd*5: 5'-CATGCCCATGG-TGAAAGACGACGGGTATGAC-3' (SEQ ID No. 1)

*lpd*3: 5'-ACGCGTCGAC-GGATGTTCCGGCAAACGAAA-3' (SEQ ID No. 2)

The chromosomal *E. coli* K12 MG1655 DNA used for the PCR is isolated with "Qiagen Genomic-tips 100/G" (QIAGEN, Hilden, Germany) in accordance with the manufacturer's instructions. An approx. 1500 bp DNA fragment can be amplified with the specific primers under standard PCR conditions (Innis et al. (1990) PCR Protocols. A Guide to Methods and Applications, Academic Press) using Pfu DNA polymerase (Promega Corporation, Madison, USA). The PCR product is ligated with vector pCR-Blunt II-TOPO (Zero Blunt TOPO PCR Cloning Kit, Invitrogen, Groningen, The Netherlands) in accordance with the manufacturer's instructions and transformed into the *E. coli* strain TOP10 (Invitrogen, Groningen, The Netherlands). Plasmid-carrying cells are selected on LB agar supplemented with 50 µg/ml of kanamycin. After isolation of the plasmid DNA, the vector is cleaved with the restriction enzymes *Nco*I and *Sal*I and, after checking in 0.8% agarose gel, is called pCRBlunt*lpd*.

Vector pCRBluntlpd is then restricted with the restriction enzymes NcoI and SalI and, after separation in 0.8% agarose gel, the lpd fragment is isolated using the QIAquick Gel Extraction Kit (QIAGEN, Hilden, Germany). Vector pTrc99A
5 (Pharmacia Biotech, Uppsala, Sweden) is cleaved with the enzymes NcoI and SalI and ligated with the isolated lpd fragment. The E. coli strain XL1-Blue MRF' (Stratagene, La Jolla, USA) is transformed with the ligation mixture and plasmid-carrying cells are selected on LB agar supplemented
10 with 50 µg/ml of ampicillin. The success of the cloning can be demonstrated, after isolation of the plasmid DNA, by control cleavage with the enzymes NcoI/SalI, EcoRV and DraIII. The plasmid is called pTrc99Alpd (Figure 1).

1b) Preparation of L-threonine with the strain
15 MG442/pTrc99Alpd

The L-threonine-producing E. coli strain MG442 is described in patent US-A-4,278,765 and is deposited in the Russian National Collection for Industrial Microorganisms (VKPM, Moscow, Russia) as CMIM B-1628.

20 The strain MG442 is transformed with expression plasmid pTrc99Alpd, described in Example 1a, and with vector pTrc99A and plasmid-carrying cells are selected on LB agar supplemented with 50 µg/ml of ampicillin. This procedure yields the strains MG442/pTrc99lpd and MG442/pTrc99A.
25 Chosen individual colonies are then multiplied further on minimum medium of the following composition: 3.5 g/l of Na₂HPO₄·2H₂O, 1.5 g/l of KH₂PO₄, 1 g/l of NH₄Cl, 0.1 g/l of MgSO₄·7H₂O, 2 g/l of glucose, 20 g/l of agar, 50 mg/l of ampicillin. The formation of L-threonine is verified in
30 10 ml batch cultures contained in 100 ml conical flasks. This is done by inoculating 10 ml of preculture medium of the following composition: 2 g/l of yeast extract, 10 g/l of (NH₄)₂SO₄, 1 g/l of KH₂PO₄, 0.5 g/l of MgSO₄·7H₂O, 15 g/l of CaCO₃, 20 g/l of glucose, 50 mg/l of ampicillin, and
35 incubating for 16 hours at 37°C and 180 rpm on an ESR

incubator from Kühner AG (Birsfelden, Switzerland). 250 µl of each of these precultures are transferred to 10 ml of production medium (25 g/l of $(\text{NH}_4)_2\text{SO}_4$, 2 g/l of KH_2PO_4 , 1 g/l of $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$, 0.03 g/l of $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$, 0.018 g/l of $\text{MnSO}_4 \cdot \text{H}_2\text{O}$, 30 g/l of CaCO_3 , 20 g/l of glucose, 50 mg/l of ampicillin) and incubated for 48 hours at 37°C. The formation of L-threonine by the original strain MG442 is verified in the same way except that no ampicillin is added to the medium. After incubation the optical density (OD) of the culture suspension is determined using an LP2W photometer from Dr. Lange (Düsseldorf, Germany) at a measurement wavelength of 660 nm.

The concentration of L-threonine formed is then determined in the sterile-filtered culture supernatant using an amino acid analyzer from Eppendorf-BioTronik (Hamburg, Germany) by means of ion exchange chromatography and postcolumn reaction with ninhydrin detection.

Table 1 shows the result of the experiment.

Table 1

Strain	OD (660 nm)	L-threonine g/l
MG442	5.6	1.4
MG442/pTrc99A	3.8	1.3
MG442/pTrc99Alpd	4.3	2.4

20

Example 2

Preparation of L-threonine using the aceE and aceF genes

2a) Construction of expression plasmid pTrc99AceEF

The aceEF gene region from E. coli K12 is amplified using the polymerase chain reaction (PCR) and synthetic

25

oligonucleotides. The nucleotide sequence of the aceE and aceF genes in E. coli K12 MG1655 (Accession Number AE000120, Blattner et al. (Science 277, 1453-1474 (1997)) is used as the starting material to synthesize PCR primers 5 (MWG Biotech, Ebersberg, Germany). The sequence of a primer is modified to create a recognition site for a restriction enzyme. The recognition sequence for SacI, which is underlined in the nucleotide sequence shown below, is chosen for the aceEF1 primer:

10 aceEF1: 5'-GATTGAGCTCTCCGGCGAGAGTTC-3' (SEQ ID No. 3)

aceEF2: 5'-ACCGGGTCGTTCTATCCGTC-3' (SEQ ID No. 4)

The chromosomal E. coli K12 MG1655 DNA used for the PCR is isolated with "Qiagen Genomic-tips 100/G" (QIAGEN, Hilden, Germany) in accordance with the manufacturer's 15 instructions. An approx. 4800 bp DNA fragment can be amplified with the specific primers under standard PCR conditions (Innis et al. (1990) PCR Protocols. A Guide to Methods and Applications, Academic Press) using *Pfu* DNA polymerase (Promega Corporation, Madison, USA). The PCR 20 product is ligated with vector pCR-Blunt II-TOPO (Zero Blunt TOPO PCR Cloning Kit, Invitrogen, Groningen, The Netherlands) in accordance with the manufacturer's instructions and transformed into the E. coli strain TOP10F'. Plasmid-carrying cells are selected on LB agar 25 supplemented with 50 µg/ml of kanamycin. After isolation of the plasmid DNA, the vector is cleaved with the restriction enzymes EcoRI and BstEII/XhoI and, after checking by separation in 0.8% agarose gel, is called pCRBluntaceEF.

30 Vector pCRBluntaceEF is then restricted with the restriction enzymes SacI and XbaI and, after separation in 0.8% agarose gel, the aceEF fragment is isolated using the QIAquick Gel Extraction Kit (QIAGEN, Hilden, Germany). Vector pTrc99A (Pharmacia Biotech, Uppsala, Sweden) is

cleaved with the enzymes SacI and XbaI and ligated with the isolated aceEF fragment. The E. coli strain XL1-Blue MRF' (Stratagene, La Jolla, USA) is transformed with the ligation mixture and plasmid-carrying cells are selected on
5 LB agar supplemented with 50 µg/ml of ampicillin. The success of the cloning can be demonstrated, after isolation of the plasmid DNA, by control cleavage with the enzymes HindIII and PstI. The plasmid is called pTrc99AaceEF (Figure 2).

10 2b) Preparation of L-threonine with the strain
MG442/pTrc99AaceEF

The L-threonine-producing E. coli strain MG442 is described in patent US-A-4,278,765 and is deposited in the Russian National Collection for Industrial Microorganisms (VKPM,
15 Moscow, Russia) as CMIM B-1628.

The strain MG442 is transformed with expression plasmid pTrc99AaceEF, described in Example 2a, and with vector pTrc99A and plasmid-carrying cells are selected on LB agar supplemented with 50 µg/ml of ampicillin. This procedure
20 yields the strains MG442/pTrc99aceEF and MG442/pTrc99A. Chosen individual colonies are then multiplied further on minimum medium of the following composition: 3.5 g/l of Na₂HPO₄·2H₂O, 1.5 g/l of KH₂PO₄, 1 g/l of NH₄Cl, 0.1 g/l of MgSO₄·7H₂O, 2 g/l of glucose, 20 g/l of agar, 50 mg/l of
25 ampicillin. The formation of L-threonine is verified in 10 ml batch cultures contained in 100 ml conical flasks. This is done by inoculating 10 ml of preculture medium of the following composition: 2 g/l of yeast extract, 10 g/l of (NH₄)₂SO₄, 1 g/l of KH₂PO₄, 0.5 g/l of MgSO₄·7H₂O, 15 g/l
30 of CaCO₃, 20 g/l of glucose, 50 mg/l of ampicillin, and incubating for 16 hours at 37°C and 180 rpm on an ESR incubator from Kühner AG (Birsfelden, Switzerland). 250 µl of each of these precultures are transferred to 10 ml of production medium (25 g/l of (NH₄)₂SO₄, 2 g/l of KH₂PO₄,
35 1 g/l of MgSO₄·7H₂O, 0.03 g/l of FeSO₄·7H₂O, 0.018 g/l of

MnSO₄·1H₂O, 30 g/l of CaCO₃, 20 g/l of glucose, 50 mg/l of ampicillin) and incubated for 48 hours at 37°C. The formation of L-threonine by the original strain MG442 is verified in the same way except that no ampicillin is added
5 to the medium. After incubation the optical density (OD) of the culture suspension is determined using an LP2W photometer from Dr. Lange (Düsseldorf, Germany) at a measurement wavelength of 660 nm.

The concentration of L-threonine formed is then determined
10 in the sterile-filtered culture supernatant using an amino acid analyzer from Eppendorf-BioTronik (Hamburg, Germany) by means of ion exchange chromatography and postcolumn reaction with ninhydrin detection.

Table 2 shows the result of the experiment.

15

Table 2

Strain	OD (660 nm)	L-threonine g/l
MG442	5.6	1.4
MG442/pTrc99A	3.8	1.3
MG442/pTrc99AceEF	3.9	1.8

Brief Description of the Figures

- Figure 1: Map of plasmid pTrc99Alpd containing the lpd gene
- 20 • Figure 2: Map of plasmid pTrac99AceEF containing the aceE and aceF genes

The indicated lengths are to be understood as approximate. The abbreviations and symbols used are defined as follows:

- Amp: ampicillin resistance gene

- lacI: gene for the repressor protein of the trc promoter
 - Ptrc: trc promoter region, IPTG-inducible
 - lpd: coding region of the lpd gene
 - 5 • aceE: coding region of the aceE gene
 - aceF: coding region of the aceF gene
 - 5S: 5S rRNA region
 - rrnBT: rRNA terminator region
 - bps base pairs
- 10 The abbreviations for the restriction enzymes are defined as follows:
- DraIII: restriction endonuclease from *Deinococcus radiophilus*
 - 15 • EcoRV: restriction endonuclease from *Escherichia coli* B946
 - HindIII: restriction endonuclease from *Haemophilus influenzae*
 - NcoI: restriction endonuclease from *Nocardia corallina*
 - 20 • PstI: restriction endonuclease from *Providencia stuartii*
 - SacI: restriction endonuclease from *Streptomyces stanford*
 - SalI: restriction endonuclease from *Streptomyces albus*
 - 25

- XbaI: restriction endonuclease from *Xanthomonas badrii*

What is claimed is:

1. A process for the preparation of L-amino acids, especially L-threonine, characterized in that the following steps are carried out:
 - 5 a) fermentation of microorganisms of the family Enterobacteriaceae which produce the desired L-amino acid and in which one or more genes selected from the group comprising lpd, aceE and aceF, or nucleotide sequences coding therefor, is (are)
10 enhanced and, in particular, overexpressed,
 - b) enrichment of the desired L-amino acid in the medium or in the cells of the microorganisms, and
 - c) isolation of the desired L-amino acid, where
15 constituents of the fermentation broth, and/or all or part (≥ 0 to 100%) of the biomass, optionally remain in the product.
2. The process according to claim 1, characterized in that microorganisms are used in which other genes of the biosynthetic pathway of the desired L-amino acid
20 are additionally enhanced.
3. The process according to claim 1, characterized in that microorganisms are used in which the metabolic pathways which reduce the formation of the desired L-amino acid are at least partially switched off.
- 25 4. The process according to claim 1, characterized in that the expression of the polynucleotide(s) coding for one or more genes selected from the group comprising lpd, aceE and aceF is increased.
- 30 5. The process according to claim 1, characterized in that the regulatory and/or catalytic properties of the polypeptides (proteins) coded for by the

polynucleotides *lpd*, *aceE* and *aceF* are improved or enhanced.

6. The process according to claim 1, characterized in that microorganisms of the family Enterobacteriaceae in which additionally one or more genes selected from the group comprising:
- 6.1 the *thrABC* operon coding for aspartate kinase, homoserine dehydrogenase, homoserine kinase and threonine synthase,
 - 6.2 the *pyc* gene coding for pyruvate carboxylase,
 - 6.3 the *pps* gene coding for phosphoenolpyruvate synthase,
 - 6.4 the *ppc* gene coding for phosphoenolpyruvate carboxylase,
 - 6.5 the *pntA* and *pntB* genes coding for transhydrogenase,
 - 6.6 the *rhtB* gene for homoserine resistance,
 - 6.7 the *mgo* gene coding for malate:quinone oxidoreductase,
 - 6.8 the *rhtC* gene for threonine resistance,
 - 6.9 the *thrE* gene coding for threonine export protein,
 - 6.10 the *gdhA* gene coding for glutamate dehydrogenase,
 - 6.11 the *hns* gene coding for DNA binding protein HLP-II,
 - 6.12 the *pgm* gene coding for phosphoglucomutase,

- 6.13 the fba gene coding for fructose biphosphate aldolase,
- 6.14 the ptsH gene coding for phosphohistidine protein hexose phosphotransferase,
- 5 6.15 the ptsI gene coding for enzyme I of the phosphotransferase system,
- 6.16 the crr gene coding for the glucose-specific IIA component,
- 10 6.17 the ptsG gene coding for the glucose-specific IIBC component,
- 6.18 the lrp gene coding for the regulator of the leucine regulon,
- 6.19 the csrA gene coding for the global regulator Csr,
- 15 6.20 the fadR gene coding for the regulator of the fad regulon,
- 6.21 the iclR gene coding for the regulator of the central intermediary metabolism,
- 6.22 the mopB gene coding for the 10 kd chaperone,
- 20 6.23 the ahpC gene coding for the small subunit of alkyl hydroperoxide reductase,
- 6.24 the ahpF gene coding for the large subunit of alkyl hydroperoxide reductase,
- 6.25 the cysK gene coding for cysteine synthase A,
- 25 6.26 the cysB gene coding for the regulator of the cys regulon,

- 6.27 the cysJ gene coding for the flavoprotein of
NADPH sulfite reductase,
- 6.28 the cysI gene coding for the hemoprotein of NADPH
sulfite reductase,
- 5 6.29 the cysH gene coding for adenylyl sulfate
reductase,
- 6.30 the phoB gene coding for the PhoB positive
regulator of the pho regulon,
- 10 6.31 the phoR gene coding for the sensor protein of
the pho regulon,
- 6.32 the phoE gene coding for protein E of the outer
cell membrane,
- 6.33 the pykF gene coding for fructose-stimulated
pyruvate kinase I,
- 15 6.34 the pfkB gene coding for 6-phosphofructokinase
II,
- 6.35 the malE gene coding for the periplasmatic
binding protein of maltose transport,
- 20 6.36 the rseA gene coding for a membrane protein with
anti-sigmaE activity,
- 6.37 the rseC gene coding for a global regulator of
the sigmaE factor,
- 6.38 the sodA gene coding for superoxide dismutase,
- 25 6.39 the sucA gene coding for the decarboxylase
subunit of 2-ketoglutarate dehydrogenase,
- 6.40 the sucB gene coding for the dihydrolipoyl
transsuccinase E2 subunit of 2-ketoglutarate
dehydrogenase,

6.41 the *sucC* gene coding for the β subunit of succinyl-CoA synthetase, and

6.42 the *sucD* gene coding for the α subunit of succinyl-CoA synthetase

5 is (are) simultaneously enhanced and, in particular, overexpressed, are fermented for the preparation of L-amino acids.

7. The process according to claim 1, characterized in that microorganisms of the family Enterobacteriaceae
10 in which additionally one or more genes selected from the group comprising:

7.1 the *tdh* gene coding for threonine dehydrogenase,

7.2 the *mdh* gene coding for malate dehydrogenase,

7.3 the gene product of the open reading frame (orf) *yjfa*,
15

7.4 the gene product of the open reading frame (orf) *ytfP*,

7.5 the *pckA* gene coding for phosphoenolpyruvate carboxykinase,

20 7.6 the *poxB* gene coding for pyruvate oxidase,

7.7 the *aceA* gene coding for isocitrate lyase,

7.8 the *dgsA* gene coding for the DgsA regulator of the phosphotransferase system,

7.9 the *fruR* gene coding for the fructose repressor,

25 7.10 the *rpoS* gene coding for the σ^{38} factor,

7.11 the *aspA* gene coding for aspartate ammonium lyase (aspartase), and

7.12 the aceB gene coding for malate synthase A

is (are) simultaneously attenuated and, in particular, switched off, or the expression is reduced, are fermented for the preparation of L-amino acids.

- 5 8. Microorganisms of the family Enterobacteriaceae, especially of the genus Escherichia, in which at least one or more genes selected from the group comprising lpd, aceE and aceF, or nucleotide sequences coding therefor, is (are) enhanced and, in particular,
10 overexpressed.



Figure 1: Map of plasmid pTrc99Alpd containing the *lpd* gene

Figure 2: Map of plasmid pTrac99AaceEF containing the aceE and aceF genes



SEQUENCE LISTING

5 <110> Degussa AG
<120> Process for the preparation of L-amino acids using strains of the family Enterobacteriaceae

10 <130> 020115 BT
<160> 4
<170> PatentIn version 3.1

15 <210> 1
<211> 30
<212> DNA
<213> Artificial sequence

20 <220>
<221> Primer
<222> (1)..(30)
<223> lpd5

25 <400> 1
catgccatgg tgaaagacga cgggtatgac 30

30 <210> 2
<211> 30
<212> DNA
<213> Artificial sequence

35 <220>
<221> Primer
<222> (1)..(30)
<223> lpd3

40 <400> 2
acgcgtcgac ggatgttccg gcaaacgaaa 30

45 <210> 3
<211> 24
<212> DNA
<213> Artificial sequence

50 <220>
<221> Primer
<222> (1)..(24)
<223> aceEF1

<400> 3
gattgagctc tccggcgaga gttc 24

55 <210> 4
<211> 20
<212> DNA
<213> Artificial sequence

5 <220>
<221> Primer
<222> (1)..(20)
<223> aceEF2

<400> 4
accggggtcgt tctatccgtc

20

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/01992

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12P13/04 C12P13/08 C12N1/21 C12N15/11 C12N15/60

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12P C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>ALLISON N ET AL: "OVEREXPRESSION AND MUTAGENESIS OF THE LIPOAMIDE DEHYDROGENASE OF ESCHERICHIA COLI"</p> <p>BIOCHEMICAL JOURNAL, PORTLAND PRESS, LONDON, GB,</p> <p>vol. 256, no. 3, 1988, pages 741-749, XP008014533</p> <p>ISSN: 0264-6021</p> <p>the whole document</p> <p style="text-align: center;">--- -/--</p>	8

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

20 June 2003

Date of mailing of the international search report

10/07/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5618 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Lopez García, F

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/01992

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 23 April 1999 (1999-04-23) NEMERIA N S ET AL: "Characterization of the pyruvate dehydrogenase E1 subunit overexpressed in Escherichia coli in the absence of E2-E3 subcomplex." Database accession no. PREV199900299126 XP002244798 the whole document & FASEB JOURNAL, vol. 13, no. 7, 23 April 1999 (1999-04-23), page A1349 Annual Meeting of the American Societies for Experimental Biology on Biochemistry and Molecular Biology 99; San Francisco, California, USA; May 16-20, 1999 ISSN: 0892-6638</p> <p>---</p>	8
X	<p>SCHULZE E ET AL: "PURIFICATION AND CELLULAR LOCALIZATION OF WILD TYPE AND MUTATED DIHYDROLIPOYLTRANSACETYLASES FROM AZOTOBACTER-VINELANDII AND ESCHERICHIA-COLI EXPRESSED IN ESCHERICHIA-COLI" BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1120, no. 1, 1992, pages 87-96, XP009012522 ISSN: 0006-3002 Abstract; p. 88, col. 2, paragraph 3; p. 89, col. 2, paragraph 5.</p> <p>---</p>	8
A	<p>EP 0 999 282 A (AJINOMOTO KK) 10 May 2000 (2000-05-10) page 8, line 27</p> <p>---</p>	1-8
A	<p>US 4 278 765 A (DEBAOV VLADIMIR G ET AL) 14 July 1981 (1981-07-14) cited in the application the whole document</p> <p>---</p>	1-8
A	<p>STEIERT P S ET AL: "THE LPD GENE PRODUCT FUNCTIONS AS THE L PROTEIN IN THE ESCHERICHIA-COLI GLYCINE CLEAVAGE ENZYME SYSTEM" JOURNAL OF BACTERIOLOGY, vol. 172, no. 10, 1990, pages 6142-6144, XP009012446 ISSN: 0021-9193 abstract</p> <p>---</p>	1-8
A	<p>EP 1 010 755 A (AJINOMOTO KK) 21 June 2000 (2000-06-21) abstract</p> <p>---</p> <p>--- -/--</p>	1-8

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/01992

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	DATABASE WPI Section Ch, Week 198848 Derwent Publications Ltd., London, GB; Class B05, AN 1988-342296 XP002244799 & JP 63 254990 A (TORAY IND INC), 21 October 1988 (1988-10-21) the whole document ---	1-8
P,X	WO 02 101064 A (DEGUSSA) 19 December 2002 (2002-12-19) abstract -----	1-8

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/01992

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0999282	A	10-05-2000	AU 5593399 A	20-04-2000
			BR 9904747 A	28-11-2000
			CN 1261627 A	02-08-2000
			EP 0999282 A2	10-05-2000
			JP 2000189175 A	11-07-2000
			KR 2000029174 A	25-05-2000
			PL 336089 A1	25-04-2000
			RU 2194076 C2	10-12-2002
US 4278765	A	14-07-1981	SU 875663 A1	15-09-1982
			HU 190999 B	28-12-1986
EP 1010755	A	21-06-2000	BR 9906279 A	24-04-2001
			CN 1270226 A	18-10-2000
			EP 1010755 A1	21-06-2000
			JP 2000232890 A	29-08-2000
JP 63254990	A	21-10-1988	JP 1681502 C	31-07-1992
			JP 3046111 B	15-07-1991
WO 02101064	A	19-12-2002	DE 10128780 A1	19-12-2002
			WO 02101068 A2	19-12-2002
			WO 02101062 A2	19-12-2002
			WO 02101063 A2	19-12-2002
			WO 02101064 A2	19-12-2002
			WO 02101054 A2	19-12-2002
			WO 02101065 A2	19-12-2002
			WO 02101066 A2	19-12-2002
			WO 02101055 A2	19-12-2002
			WO 02101050 A2	19-12-2002
			WO 02101067 A2	19-12-2002
			US 2003064485 A1	03-04-2003
			US 2003087404 A1	08-05-2003
			US 2003092138 A1	15-05-2003
			US 2003100081 A1	29-05-2003

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☒ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.